Literature DB >> 14961557

A novel PTPN11 mutation in LEOPARD syndrome.

E Conti1, T Dottorini, A Sarkozy, G E Tiller, G Esposito, A Pizzuti, B Dallapiccola.   

Abstract

PTPN11 gene mutations are common to both patients with Noonan (NS) and LEOPARD syndrome (LS). So far only two recurrent mutations have been identified in LS patients by different research groups, i.e., Tyr279Cys and Thr468Met. In this work we describe the third PTPN11 mutation that has been found in a single LS patient. The mutation (c.1517A>C) substitutes a proline for a glutamine at amino acid 506 (Gln506Pro) in the phosphatase domain (PTP) of the PTPN11 peptide SHP2. This region is a mutation hotspot. Changes at amino acids 501 to 504 cause NS. Gln506Pro is predicted, by modeling analysis, to seriously disrupt the normal contacts between the regulating N-SH2 and the active PTP domains, leading to hyperactivity of the phosphatase. This report demonstrates that rarer mutations other than Tyr279Cys and Thr468Met can be found in LS patients and the need of screening the whole gene in those negative for the commonest mutations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14961557     DOI: 10.1002/humu.9149

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.

Authors:  Kamini Kalidas; Adam C Shaw; Andrew H Crosby; Ruth Newbury-Ecob; Lynn Greenhalgh; Isabel K Temple; Caroline Law; Amisha Patel; Michael A Patton; Steve Jeffery
Journal:  J Hum Genet       Date:  2004-12-10       Impact factor: 3.172

2.  PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".

Authors:  M Cristina Digilio; Anna Sarkozy; Giuseppe Pacileo; Giuseppe Limongelli; Bruno Marino; Bruno Dallapiccola
Journal:  Eur J Pediatr       Date:  2006-05-30       Impact factor: 3.183

Review 3.  LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature.

Authors:  Ingrid Kalev; Kai Muru; Rita Teek; Riina Zordania; Tiia Reimand; Kristel Köbas; Katrin Ounap
Journal:  Eur J Pediatr       Date:  2009-09-20       Impact factor: 3.183

4.  Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes.

Authors:  Joanne Soong; Glynis Scott
Journal:  J Cell Sci       Date:  2012-11-30       Impact factor: 5.285

5.  Induction of SHP2 deficiency in chondrocytes causes severe scoliosis and kyphosis in mice.

Authors:  Harry K W Kim; Olumide Aruwajoye; Daniel Sucato; B Stephens Richards; Gen-Sheng Feng; Di Chen; Philip D King; Nobuhiro Kamiya
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-01       Impact factor: 3.468

6.  Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions.

Authors:  Harry K W Kim; Gen-Sheng Feng; Di Chen; Philip D King; Nobuhiro Kamiya
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

7.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Simone Martinelli; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Viviana Cordeddu; Giuseppe Zampino; Ineke van der Burgt; Antonio Palleschi; Tamara C Petrucci; Mariella Sorcini; Claudia Schoch; Robin Foa; Peter D Emanuel; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2005-12-07       Impact factor: 11.025

Review 8.  Functions of Shp2 in cancer.

Authors:  Jie Zhang; Fei Zhang; Ruifang Niu
Journal:  J Cell Mol Med       Date:  2015-06-19       Impact factor: 5.310

Review 9.  Leopard syndrome.

Authors:  Anna Sarkozy; Maria Cristina Digilio; Bruno Dallapiccola
Journal:  Orphanet J Rare Dis       Date:  2008-05-27       Impact factor: 4.123

Review 10.  Molecular screening strategies for NF1-like syndromes with café-au-lait macules (Review).

Authors:  Jia Zhang; Ming Li; Zhirong Yao
Journal:  Mol Med Rep       Date:  2016-09-22       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.